What one share of Molecular Partners Ag holds
We are a clinical-stage biotechnology company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address. We have programs in various stages of preclinical and clinical development, currently with main focus on oncology.
Molecular Partners Ag’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.00 |
|---|---|
| Profit | −$2.00 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.68 |
| Cash and investments | $2.58 |
| Book value | $2.51 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.96 | −$1.71 | $0.05 | −$0.10 | — | $2.59 |
| 2020 | $0.40 | −$2.68 | $0.06 | −$1.30 | — | $4.16 |
| 2021 | $0.34 | −$2.25 | $0.03 | −$3.24 | — | $3.63 |
| 2022 | $5.97 | $3.71 | $0.04 | $3.70 | — | $7.06 |
| 2023 | $0.24 | −$2.11 | $0.02 | −$2.02 | — | $5.77 |
| 2024 | $0.17 | −$1.80 | $0.02 | −$2.00 | — | $3.87 |
| 2025 | $0.00 | −$2.00 | $0.02 | −$1.68 | — | $2.51 |
Common questions about Molecular Partners Ag
How much does one share of Molecular Partners Ag earn?
Over its latest fiscal year, Molecular Partners Ag lost $2.00 for each share.
Does Molecular Partners Ag pay a dividend?
Molecular Partners Ag didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Molecular Partners Ag’s book value per share?
Molecular Partners Ag’s book value is $2.51 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Molecular Partners Ag have?
Each share of Molecular Partners Ag has $2.58 of cash and investments, as of December 31, 2025.
What is Molecular Partners Ag’s free cash flow per share?
−$1.68 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Molecular Partners Ag bought back shares?
Molecular Partners Ag’s share count rose about 74% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.